Literature DB >> 22424278

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22424278     DOI： 10.1016/j.ejca.2011.12.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  191 in total

1.  Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response.

Authors:  F H Cornelis; A Borgheresi; E N Petre; E Santos; S B Solomon; K Brown
Journal:  Cardiovasc Intervent Radiol       Date:  2017-08-02       Impact factor: 2.740

2.  The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.

Authors:  Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2015-11

3.  Central Hepatectomy Still Plays an Important Role in Treatment of Early-Stage Centrally Located Hepatocellular Carcinoma.

Authors:  Chun-Han Chen; Tzu-Hao Huang; Cheng-Chih Chang; Wei-Feng Li; Ting-Lung Lin; Chih-Chi Wang
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

4.  Glutathione S-transferase O2 gene rs157077 polymorphism predicts response to transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Zhixin Wang; Kai Qu; Zhichao Huang; Xinsen Xu; Jingyao Zhang; Li Zhang; Sinan Liu; Hulin Chang; Ting Lin; Yamin Liu; Wenquan Niu; Chang Liu
Journal:  Tumour Biol       Date:  2015-04-03

5.  Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.

Authors:  Yi-Chia Chan; Catherine S Kabiling; Vinod G Pillai; Gustavo Aguilar; Chih-Chi Wang; Chao-Long Chen
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

6.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

Review 7.  LI-RADS 2017: An update.

Authors:  Ania Z Kielar; Victoria Chernyak; Mustafa R Bashir; Richard K Do; Kathryn J Fowler; Donald G Mitchell; Milena Cerny; Khaled M Elsayes; Cynthia Santillan; Aya Kamaya; Yuko Kono; Claude B Sirlin; An Tang
Journal:  J Magn Reson Imaging       Date:  2018-04-06       Impact factor: 4.813

Review 8.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

9.  Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).

Authors:  Hisashi Hidaka; Namiki Izumi; Takeshi Aramaki; Masafumi Ikeda; Yoshitaka Inaba; Kazuho Imanaka; Takuji Okusaka; Susumu Kanazawa; Shuichi Kaneko; Shinichi Kora; Hiroya Saito; Junji Furuse; Osamu Matsui; Tatsuya Yamashita; Osamu Yokosuka; Satoshi Morita; Hitoshi Arioka; Masatoshi Kudo; Yasuaki Arai
Journal:  Med Oncol       Date:  2019-05-03       Impact factor: 3.064

10.  Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3 cm.

Authors:  Alessia Guarneri; Pierfrancesco Franco; Elisabetta Trino; Daniela Campion; Riccardo Faletti; Stefano Mirabella; Silvia Gaia; Riccardo Ragona; Margherita Diotallevi; Giorgio Saracco; Mauro Salizzoni; Umberto Ricardi; Patrizia Carucci
Journal:  Med Oncol       Date:  2016-08-26       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.